Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Minerva Neurosciences Inc. buy geldnutzer

Start price
€5.88
19.05.23 / 50%
Target price
€7.00
19.05.24
Performance (%)
-62.93%
Price
€2.26
29.04.24
Summary
This prediction is currently active. The BUY prediction by geldnutzer for Minerva Neurosciences Inc. is performing very badly with a performance of -62.93%. This prediction currently runs until 19.05.24. The prediction end date can be changed by geldnutzer at any time. geldnutzer has 50% into this prediction

Minerva Neurosciences (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from neuropsychiatric disorders. With a primary emphasis on central nervous system diseases such as schizophrenia, major depressive disorder, insomnia, and Parkinson's, Minerva Neurosciences is committed to addressing unmet medical needs and advancing the understanding of the underlying biology of these conditions. Utilizing a strong research and development platform, the company aims to create a diversified portfolio of novel therapies that have the potential to significantly improve patients' quality of life and help them lead more fulfilling lives.

Performance without dividends (%)
Name 1w 1m
Minerva Neurosciences Inc. -5.042% -5.042%
iShares Core DAX® 0.961% -2.210%
iShares Nasdaq 100 2.626% -1.918%
iShares Nikkei 225® 0.217% -7.216%
iShares S&P 500 1.540% -1.858%

According to geldnutzer what are the pros and cons of Minerva Neurosciences Inc. for the foreseeable future?

Pros
Standard Investments for future growth
Higher EBIT margin than peer group
Fair valuation
Good culture
Innovative
Growths faster than the competition
Differentiated customer and product portfolio
Top 10 in its market
Known brand
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Normal challenges to pay loans and raise capital
Capable Management
Cons
Very low/no dividend yield expected
ROE lower than 10% per year
Few uniques
Sustainability is little important
Higher risks for its business
Significant cyclical dependencies

Comments by geldnutzer for this prediction

In the thread Minerva Neurosciences Inc. diskutieren
Prediction Buy
Perf. (%) -62.93%
Target price 6.600
Change
Ends at 19.05.24

Buy mit Kursziel 6,6

Prediction Buy
Perf. (%) -62.93%
Target price 6.000
Change
Ends at 19.05.24

Kursziel geändert auf 6,0

Prediction Buy
Perf. (%) -62.93%
Target price 11.000
Change
Ends at 19.05.24

Kursziel geändert auf 11,0

Prediction Buy
Perf. (%) -62.93%
Target price 10.000
Change
Ends at 19.05.24

Kursziel geändert auf 10,0

Prediction Buy
Perf. (%) -62.93%
Target price 7.000
Change
Ends at 19.05.24

Kursziel geändert auf 7,0

Stopped prediction by geldnutzer for Minerva Neurosciences Inc.

Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€3.19
11.06.22
€1.60
11.06.23
84.40%
19.05.23

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€4.81
14.03.22
€6.40
14.03.23
-33.68%
11.06.22

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€5.39
30.01.22
€4.00
30.01.23
-10.83%
14.03.22

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€6.41
20.12.21
€7.20
20.12.22
-15.91%
30.01.22

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€16.08
24.06.21
€4.80
24.06.22
-60.12%
20.12.21

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€18.77
11.06.21
€23.20
11.06.22
-14.32%
24.06.21

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€15.25
06.05.21
€18.40
06.05.22
23.09%
11.06.21

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€23.36
20.02.21
€26.40
20.02.22
-34.73%
06.05.21

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€16.64
22.12.20
€14.40
22.12.21
40.38%
20.02.21

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€23.20
13.10.20
€19.20
04.11.21
-28.28%
22.12.20

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€22.56
15.08.20
€16.00
13.10.20
2.84%
13.10.20

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€25.12
03.08.20
€32.00
15.08.20
-10.19%
15.08.20

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€24.48
25.07.20
€16.00
03.08.20
2.61%
03.08.20

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year